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Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Str. 1, 30655 Hannover, GermanyPrimary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by progressive inﬂammation and
ﬁbrosis of the bile ducts, resulting in biliary cirrhosis and is associated with a high risk of cholangiocarcinoma. The majority
of patients are young, male and have coexisting inﬂammatory bowel disease. PSC is found with a prevalence of 10/100,000
in Northern European populations. The pathophysiology of PSC is a complex multistep process including immunological mech-
anisms, immunogenetic susceptibility and disorders of the biliary epithelia. The diagnosis is primarily based on endoscopic chol-
angiography although magnetic resonance imaging is increasingly used; biochemistry and immunoserology as well as histology
play only a minor role. Due to the high risk of developing cholangiocarcinoma and also other tumours of the GI tract, surveillance
strategies are essential, however they have yet to be established and evaluated. Biochemical parameters, clinical risk factors,
endoscopic procedures and imaging techniques contribute to the early identiﬁcation of patients at risk. Since medical therapy
of PSC with ursodeoxycholic acid does not improve survival, to date, liver transplantation is the only option with a cure potential;
if transplantation is accurately timed, transplanted PSC patients have an excellent rate of survival. However if cholangiocarci-
noma is detected, a curative treatment is not possible in the majority of cases. The present review critically summarizes the
current knowledge on the aetiopathogenesis of PSC and gives an overview of the diagnostic approaches, surveillance strategies
and therapeutic options. Primary sclerosing cholangitis is a disease of unknown aetiology and without any further curative
treatment options apart from liver transplantation. Therefore it may be regarded as the greatest challenge in hepatology today.
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Primary sclerosing cholangitis (PSC) is a chronic and
progressive cholestatic liver disease, which is character-
ized by inﬂammation and ﬁbrosis of mainly the large
bile ducts leading to biliary cirrhosis in a high percent-
age of patients. It is associated with inﬂammatory bowel
disease (IBD) in the majority of cases and is associated
with a high risk of hepatobiliary as well as extrahepatic
malignancies.
In 1929, J.A. Bargen described a case of a biliary cir-
rhosis in a patient with ulcerative colitis (UC); this was
the ﬁrst description of this disease in English [1] and sub-
sequently he observed further cases of hepatic lesions in
UC. In a series of 93 patients with UC, Kimmelstiel
et al. reported in 1950 an increased frequency of liver
damage [2], including bile casts and interlobular hepati-
tis. The term ‘‘Primary sclerosing cholangitis” was ﬁrst
coined in the early 1960s, when the diagnosis of this dis-
ease was based primarily on ﬁndings at laparotomy; but
it was not until retrograde cholangiography by ﬁber
duodenoscope introduced in 1970, that this disease
became easier to diagnose and later also easier to treat.
During the last three decades signiﬁcant progress was
made regarding the diagnostic and therapeutic methods,
but still we are facing important challenges: the aetio-
pathogenesis of PSC remains poorly understood, the
medical treatment of PSC is insuﬃcient and the early
detection of malignant complications to allow timely
therapy, namely, liver transplantation is diﬃcult.
Data on the epidemiology of PSC are rare and origi-
nate from a few major tertiary referral centres in North-
ern Europe or North America. In addition, the studies
available mostly have methodological limitations [3].
Furthermore, PSC obviously does not occur with the
same frequency worldwide. In Northern Europe, Canada
or Minnesota incidence rates between 0.9 and 1.3/
100,000/year and prevalence between 8.5 and 13.6/
100,000 have been reported [4–7], while in southern Eur-
ope, Asia or Alaska this disease is seen much less fre-
quently [8–11]. Between 55% and 71% of the patients
aremale and themean age at diagnosis is around 40 years;
a concomitant IBD can be found in 62–73% of patients
and conversely 3–4% of patients with IBD have also
PSC [3,12]. Ulcerative colitis (UC) is most common, but
an association with Crohn’s disease has been described
in 1–14% of all PSC patients. However, in Japan [10]
and Singapore [9] patients appear to be older at diagnosis
and an associated IBD is less frequent. As numerous stud-
ies demonstrated, PSC is a disease of non-smokers, since
current smokers have a decreased risk with an odds-ratio
of 0.13–0.17 for the development of PSC [13,14].
The clinical course of PSC is characterized by recur-
rent episodes of cholangitis, during which the disease
slowly progresses. While patients are initially often
asymptomatic, they suﬀer over the years from jaundice,pruritus, fever and ﬁnally all the symptoms of end-stage
liver disease can appear. Nevertheless in some patients
the disease can also rapidly progress when after a period
of stability septic biliary complications occur. The main
causes of death are cholangiocarcinoma and liver fail-
ure. The mean time from diagnosis to death or liver
transplantation ranges from 9.6 to 12 years and cholan-
giocarcinoma develops in 8–13.2% [15–17].2. Aetiology and pathogenesis
While the cause of PSC still remains unknown, there
are currently numerous approaches evolving that help us
to understand the multiple mechanisms involved in aeti-
opathogenesis [18]. Based on an adequate immunoge-
netic background, immunopathogenetic mechanisms
occur, which cause inﬂammatory changes of the bile
ducts possibly triggered or intensiﬁed by infectious
pathogens [19,20]. The following review describes sev-
eral aspects of the aetiopathogenesis of PSC, i.e. PSC
as a genetic disease, as an autoimmune disease, as an
inﬂammatory disease triggered by infectious agents
and as a cholangiopathy (Table 1).
2.1. PSC as a genetic disease
First-degree relatives of PSC patients have a PSC
prevalence of 0.7% and siblings have an even higher
prevalence of 1.5% [21]; this approximately 100-fold
increased risk of PSC between genetically related indi-
viduals illustrates the importance of a genetic predispo-
sition for the development of the disease. However, PSC
is a complex non-mendelian disorder and the suscepti-
bility to the disease is probably based on a combination
of certain alleles of the major histocompatibility com-
plex (MHC) and other non-MHC gene-polymorphisms.
The MHC encodes among others the human leuko-
cyte antigen (HLA) class I and HLA class II molecules,
which are involved in T-cell response, as well as the
MHC class I chain-like (MIC)a-molecules, which play
a role for the innate immune response, especially as
ligands for natural killer cells [18,19,22]. MHC-haplo-
types with an increased risk of PSC include several risk
alleles like MICA  008, DRB1  0301, DRB1  1301 or
DRB1  1501; the strongest association was found for
the MICA  008-homozygosity with an odds-ratio of
5.01. Other haplotypes like DRB1  0701, DRB1  0401
and MICA  002 are found in lower frequency in
patients with PSC compared with controls and hence
they are designated as protective haplotypes with an
reduced risk of PSC development [23–25].
Genes outside the MHC-region also contribute to the
susceptibility to PSC or inﬂuence the disease progression;
most of them are involved in immune regulation. Unfor-
tunately, most of the studies describing an inﬂuence of
Table 1
Summary of the current pathogenetic concepts possibly involved in the aetiology of primary sclerosing cholangitis
Pathogenetic concept Pros Cons
PSC as genetic disease – Increased prevalence of PSC among ﬁrst-degree
relatives [21]
– Association with HLA-haplotypes is only weak
and not mandatory
– Association with certain MHC- and non-MHC-alleles
[23–31]
– Studies on non-HLA polymorphisms are not
reproducible or contradictory
PSC as an autoimmune
disease
– Increased incidence of co-existing autoimmune
diseases [20]
– No response on immunosuppressive treatment
– Presence of multiple autoantibodies [33] – Male predominance
– Antibodies are not speciﬁc and do not correlate
with clinical parameters
PSC as inﬂammatory reaction
on infectious agents
– Co-expression of VAP-1 and MadCAM-1 in the
gut and the liver of patients with PSC and IBD
allows an enterohepatic lymphocyte circulation
[41,42,44,45]
– In PSC patients without IBD enterohepatic
lymphocyte circulation is not a conclusive concept
– In a rat model small intestinal bacterial overgrowth lead
to biliary strictures and portal inﬂammation [48]
– No evidence of sign. bacteraemia in UC [46]
– Helicobacter species can be found in 24–75% of PSC
livers [50,52]
– No evidence of small intestinal bacterial
overgrowth or disturbed intestinal permeability
in PSC patients [49]
– Helicobacter species are not found more often in
livers of PSC patients than in non-cholestatic
liver diseases [51]
PSC as a cholangiopathy – Knockout of the Mdr2 gene which encodes a canalicular
phospholipid transporter in mice, results in a sclerosing
cholangitis [61,62]
– In human PSC patients a signiﬁcant variation
of the corresponding MDR3-gene could not
be found [63]
– Sera of PSC patients contain autoantibodies against a
shared peptide in biliary and colon epithelium [65]
– Biliary epithelial cells that are activated by
serum-autoantibodies produce cytokines and trigger
inﬂammation [66,67]
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ducible. For instance a 32-bp deletion of the chemokine
receptor 5 (CR5D32), which is frequently found inNorth-
ern European countries, results in a reduced receptor
expression on T-cells; a recent study on a Belgian popula-
tion showed a signiﬁcant lower frequency of this muta-
tion compared with healthy control subjects suggesting
a protective eﬀect [26]. However, this is in contrast to a
previous study from Australia, which found a higher fre-
quency of CR5D32 in PSC patients [27]. E469E-homozy-
gosity of the intercellular adhesion molecule (ICAM)-1
was associated with protection against PSC in one study
[28], but again this ﬁnding was not reproducible in a big-
ger subsequent study [29]. Another polymorphism with
an increased PSC-susceptibility is the G to A substitution
at position 308 in the TNF-a promoter [30].
The ﬁndings regarding a role of the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) are also
contradictory; while one study demonstrated an
increased prevalence of CFTR abnormalities in PSC
patients, these results were not conﬁrmed by others
[31,32].
2.2. PSC as an autoimmune disease
The described strong association of PSC-susceptibil-
ity and progression with certain HLA-haplotypes as wellas with other immune-regulating gene-polymorphisms
(e.g. ICAM-1, CR5D32) underlines the fundamental role
of immunogenetic mechanisms in the pathogenesis of
PSC. The hypothesis of PSC as an autoimmune disease
is supported by the high frequency of inﬂammatory
bowel disease in PSC patients, the increased incidence
of other coexisting autoimmune diseases [20] and the
presence of multiple autoantibodies [33]. Nevertheless,
because of its male predominance, its non-response on
immunosuppressive treatment and the missing evidence
of an PSC-speciﬁc autoantigen, PSC must be regarded
with caution as an autoimmune disease [18,19].
In PSC multiple non-speciﬁc autoantibodies, which
are rather an epiphenomena to chronic inﬂammation,
can be found; these include antinuclear antibodies
(ANA) in 7–77%, anticardiolipin antibodies in 4–66%,
anti-smooth-muscle antibodies in 13–20%, anti-thyroid
peroxidase (TPO) antibodies in 16% and rheumatoid
factor in 15% [19,33]. Atypical perinuclear-staining,
antineutrophil cytoplasmic antibodies (p-ANCA) can
be found in 60–93% of patients with PSC but also in
patients with AIH, PBC or UC [34–36]. Terjung et al.
identiﬁed a 50-kDa nuclear envelope protein as target
antigen in 92% of atypical p-ANCA and proposed the
more accurate term ‘‘peripheral antineutrophil nuclear
antibodies” (p-ANNA) [37]; nevertheless it is still ques-
tionable, whether this target protein or p-ANNAs are
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signiﬁcant diagnostic role to ANCAs as the only anti-
bodies in PSC; however, there is no clear correlation
of ANCA-serum-titers and clinical parameters, so they
are not helpful in clinical management.
Further hints of an involvement of humoral immu-
nity are the early observations of elevated circulating
immune complexes [38] as well as the complement acti-
vation with elevated C3d and C4d in PSC compared
with obstructive cholestasis [39].
The ﬁnding of a T-cell predominant portal inﬁltrate
indicates the role of cellular immunity in PSC [19]. Indeed
the function of liver derived T lymphocytes of PSC
patients seems to be considerably altered by a TNF-a
dependent mechanism with impaired cytokine produc-
tion and reduced proliferative responses to mitogens [40].
In consideration of the strong link between PSC and
IBD, the hypothesis of an enterohepatic circulation of
lymphocytes generated in the gut occurred, which persist
as long-lived memory cells and upon activation trigger
hepatic inﬂammation; this concept explains why PSC
sometimes develops even many years after proctocolec-
tomy [41,42]. The recirculation could be facilitated by
the co-expression of vascular adhesion protein (VAP)-
1 [43] and mucosal addressin cell adhesion molecule
(MadCAM)-1 [44] in both organs in patients with PSC
and IBD, while under normal conditions their expres-
sion is restricted to the gut (MadCAM-1) resp. the liver
(VAP-1). Livers of patients with PSC showed strong
expression of CCL25, a chemokine normally expressed
only in the gut and thymus; it allows CCR9+ T-cells,
which are generated during colonic inﬂammation, to
inﬁltrate the liver by adhesion to MadCAM-1 [45].
2.3. PSC as an inﬂammatory reaction to infectious agents
Some authors see PSC as an immune-mediated
inﬂammatory disease rather than as an autoimmune dis-
ease. This would be consistent with a role of bacterial or
viral antigens, which enter the portal circulation through
the mucosa in IBD and trigger as molecular mimics an
immune reaction leading to PSC. However, in a study
on eight patients with UC no signiﬁcant bacteraemia
was veriﬁed in specimens of mesenteric and peripheral
venous blood obtained during surgery for uncontrolled
disease [46]; moreover in histological studies portal phle-
bitis in PSC was usually mild and did not diﬀer from
patients with UC without PSC [47]. Small intestinal bac-
terial overgrowth lead to biliary strictures and portal
inﬂammation in a rat model [48], but it does not seem
to contribute to the pathogenesis of PSC in humans;
in a study on 22 PSC patients only one showed signiﬁ-
cant small intestinal bacterial overgrowth and the intes-
tinal permeability was normal in all patients [49].
Current data concerning a possible role of helicobac-
ter species in the pathogenesis of PSC are controversial.In a ﬁrst study using PCR techniques to identify helico-
bacter in liver biopsies, 9 of 12 (75%) samples from PSC
patients and 11 of 12 samples from PBC patients were
positive, while all the normal livers and 92% of non-
cholestatic cirrhotic livers were negative; furthermore
PSC patients with UC were more likely to be positive
[50]. Nonetheless, a subsequent study could detect heli-
cobacter species only in 5 of 13 PSC livers as well as
in 10 of 29 non-cholestatic livers and therefore dis-
claimed an inﬂuence of helicobacter on PSC [51]. A
recent study also found helicobacter positive PCR in
only 24% of PSC livers and 9.7% of non-biliary liver dis-
eases [52].
Some authors suspected viruses like Cytomegalovirus
or Reovirus type 3 played a role in PSC pathogenesis,
however, more comprehensive studies did not support
this hypothesis [53,54].
Numerous studies analyzed bile obtained during
ERCP and found enteric bacteria [55,56] or even fungal
infections with Candida [57]; yet these ﬁndings were
more frequent in patients with previous ERCP and/or
with dominant stenoses so that bile duct infections
seemed to be more relevant for PSC progression rather
than for aetiopathogenesis and primary manifestation
of the disease.
Altogether, infectious agents probably do not directly
cause PSC but could activate an immune reaction by the
above mentioned enterohepatic lymphocyte circulation
or could accelerate disease progression when leading
to a biliary infection.
2.4. PSC as a cholangiopathy
PSC is a disease mainly of the large bile ducts and
belongs to the cholangiopathies, a group of various
hereditary or acquired diseases of the biliary tree with
cholestasis as a common symptom and with cholangio-
cytes as primary target cells of the disease process
[58,59].
The complex osmotic secretory process of bile forma-
tion depends on a number of membrane transport sys-
tems including ion transporters and organic-solute
transporters. These transporters are diﬀerentially
expressed on the sinusoidal and the canalicular mem-
brane of hepatocytes and on biliary epithelial cells
(BEC) [60]. Knockout of the Mdr2 gene, which encodes
a canalicular transporter for phospholipids in mice,
causes absence of phospholipids in bile and leads to a
sclerosing cholangitis with hepatobiliary changes that
resemble PSC in humans. Interestingly enough, feeding
of ursodeoxycholic acid (UDCA) in these mice lowered
alkaline phosphatase levels but increased alanine amino-
transferase levels and led to bile infarcts, while 24-nor-
UDCA improved liver tests and liver histology [61,62].
Although in human PSC patients signiﬁcant variations
of the corresponding MDR3, the human equivalent of
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mouse model directs attention to a possible role of hepa-
tobiliary transporters and changes of bile composition
and may help to understand some pathogenetic and
therapeutic principals in PSC.
Das et al. looked into the issue of how BEC become
the target of an immune reaction in patients with PSC
and UC. They developed murine monoclonal antibodies
against a colonic protein that reacts with IgG from
colon specimens solely of UC patients. This antibody
reacted additionally with mucosal or epidermal epithe-
lial cells of the gall bladder, the bile duct, the hepatic
ducts and the skin, but not with other organs such as
synovia, eye tissue or the small intestine [64]. In contrast
to patients with PBC, other liver diseases or normal con-
trols, approximately two-thirds of the sera of patients
with PSC contained autoantibodies against this epitope
[65], and therefore, it might be a candidate as a target
protein for immune reaction on biliary epithelia in
patients with UC.
The group from the Karolinska Institute in Sweden
found antibodies against isolated BEC in the sera of
63% of PSC patients which induced BEC to produce
high levels of interleukin (IL) 6 and increased the expres-
sion of the adhesion molecule CD44 [66]. A recent study
from the same group demonstrated that the stimulation
of BEC with these antibodies induced the expression of
Toll-like receptors (TLR), extracellular signal-regulated
kinase and transcription factors. When further stimu-
lated with lipopolysaccharide the TLR expressing BEC
produced high levels of cytokines such as IL8, interferon
c (IFNc) and tumour necrosis factor a (TNF-a) [67]. As
previous studies from Spirli et al. showed, each combi-
nation of IL6, IL1, TNF-a or IFNc stimulated biliary
epithelia to generate NO and thus inhibited cAMP-
dependent ﬂuid secretion of isolated bile duct units
[68,69]. In summary, these ﬁndings clarify how anti-
body-activated BEC further stimulated by bacterial
products, trigger chronic inﬂammation which leads to
ductular cholestasis.
2.5. Aetiopathogenesis of malignancies in PSC
Chronic inﬂammatory diseases such as PSC are fre-
quently linked with an enhanced risk for cancer. A very
large study compared the risk of extra- and intrahepatic
malignancies during a median follow-up period of 5.7
years (0–27.8) in 604 PSC patients with that of the gen-
eral Swedish population [15]. The frequency of hepatob-
iliary cancer in PSC patients was 13.3% and 37% of
these malignancies were diagnosed less than one year
after PSC was diagnosed. It has been estimated that
the incidence of cholangiocarinoma (CC) in PSC
patients is 1–1.5% per year. In addition to the 161-fold
increased risk for hepatobiliary cancer, PSC patients
showed a 10-fold risk for colorectal cancer and a 14-foldrisk for pancreatic cancer compared to the general
population.
CC can arise at any stage of PSC and is the leading
cause of death in these patients. It develops either as a
mass lesion in the liver or as a ductal carcinoma in the
biliary tree with a ratio of 1:4 to 1:7 in diﬀerent studies
[70]. In patients with PSC, cholangiocarcinoma occurs
approximately in 15% in the liver, 20% in the distal com-
mon biliary duct, and in 65% in the hilar region. The
risk factors for cholangiocarcinogenesis in PSC patients
are poorly deﬁned. Smoking and alcohol consumption
have been suggested as risk factors while duration of
PSC or inﬂammatory bowel disease appears not to be
associated with an increased risk for CC in PSC
patients.
The pathogenesis and molecular mechanisms of CC
development in PSC are poorly understood. In experi-
mental models, bile has been shown to induce oxidative
stress and to up-regulate genes involved in carcinogene-
sis [71]. In PSC patients, the cholangiocytes are exposed
to cytokines of inﬂammatory pathways such as interleu-
kin-6 which prolongs survival of malignant cholangio-
cytes [72]. In addition, several investigations have
suggested that inﬂammatory cytokines cause inducible
nitric oxide synthase (iNOS) expression in cholangio-
cytes with peroxynitrite formation, oxidative DNA
damage and inhibition of DNA repair. Subsequent
accumulation of mutations in tumour suppressor genes
and oncogenes as well as development of genetic insta-
bility ﬁnally leads to dysplasia of biliary epithelia and
CC. Little is known about a characteristic pattern or
hierarchy of diﬀerent molecular alterations in PSC-asso-
ciated CC. There are few data regarding molecular alter-
ations in k-ras, an important oncogene, and p53 one of
the most important tumour suppressor genes. Onco-
genic k-ras mutations are present in approximately
30% of the PSC-related CC, and overexpression of p53
or p53 mutations has been observed in 30–80% of these
tumours [73,74]. p53 mutations seem to occur only in
malignant tissue, while k-ras mutations are also
observed in dysplasia of bile duct epithelia in PSC
patients, which suggest that, in contrast to p53 muta-
tions, k-ras mutation is an early event in PSC-related
cholangiocarcinogenesis. The p16INK4a is a major reg-
ulator of the cell cycle and also frequently altered in dif-
ferent tumour types. Several studies showed that
p16INK4a inactivation by chromosome 9p21 loss,
mutations within the coding gene and mutations or
methylation of the p16INK4a promoter is common in
PSC-associated cholangiocarcinoma [75,76].
On the whole, PSC appears to be caused by a com-
plex interaction between deregulated immune mecha-
nisms in genetically predisposed persons and
environmental factors such as infectious agents. How-
ever, this multitude of possible pathogenetic processes
should allow the question, as to whether PSC is perhaps
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of similar diseases with diﬀerent aetiologies. Tumour
development of the liver, CC but also HCC, and extra-
hepatic tissues such as pancreas and colon in PSC still is
a black box. However, bringing light into this complex
area may give signiﬁcant clues to this overall poorly
understood and mysterious disease.3. Diagnosis of PSC
The clinical symptoms described in PSC as well as the
laboratory tests are not speciﬁc but result in further
diagnostic steps such as cholangiography, magnetic res-
onance imaging or liver biopsy. The deﬁnite diagnosis of
PSC cannot be conﬁrmed until secondary causes of cho-
langitis are ruled out.
3.1. Clinical presentation
At the time of diagnosis, a considerable proportion of
the patients (21–44%) is asymptomatic [6,17,77] and is
identiﬁed just through incidental or selective (in case
of IBD) testing of the liver enzymes. One recent study
showed that in contrast to the period 1984–1998,
patients in the following 6 years (1998–2004) were more
often asymptomatic and older when ﬁrst diagnosed or
diagnosed in earlier pre-cirrhotic stages and presented
less frequently with associated IBD [78].
Symptomatic patients present frequently with
abdominal pain (33–37%), jaundice (27–30%) or pruri-
tus (20–40%) and with fever (11–35%). Other common
ﬁndings in clinical examinations and abdominal ultra-
sound are hepatomegaly (44–55%) or splenomegaly
(29–30%). Only 2–4% patients have ascites and 2.6–6%
have a history of variceal bleeding prior to diagnosis
[16,17,78,79]. The general prevalence of esophageal var-
ices diagnosed by upper endoscopy varies from 7% to
36% [17,80]. Fatigue was described as a common symp-
tom in PSC. However, a sophisticated study addressing
this issue demonstrated that fatigue did not diﬀer in PSC
patients and patients with IBD alone, and that its prev-
alence was even lower than in age- and sex-matched sub-
jects from the general population [81].
Cholangiocarcinoma is found in 3.3% of PSC
patients within the ﬁrst 3 months after diagnosis, and
in 5% within the ﬁrst year. These patients tend to be
more symptomatic on initial diagnosis; therefore, the
ﬁrst clinical evaluation is of particular importance
[15,17,82].
Apart from the well-known association with IBD
more than 20% of PSC patients display at least one
additional extraintestinal autoimmune feature: most fre-
quently, insulin dependent diabetes mellitus was found
in 10.1%, thyroid disorders in 8.4% and psoriasis in
4.2% [20].Another frequent ﬁnding in more advanced stages of
the disease is an osteopenic bone disease with 50% of the
patients having a bone mineral density below the frac-
ture threshold [83].
3.2. Biochemistry and immunoserology
PSC patients typically present with a cholestatic bio-
chemical proﬁle with 3–10 times of the upper limit
increased levels of the serum alkaline phosphatase
(AP). However, this ﬁnding is neither speciﬁc nor man-
datory [79,84]. Slight increases of the serum aminotrans-
ferase values are also frequently found. Serum bilirubin
levels are usually normal at the beginning, but with pro-
gression of the disease they increase with ﬂuctuations
due to choledocholithiasis or dominant stenoses. Since
hepatic synthesis function is initially unimpaired,
parameters like albumin, cholinesterase or prothrombin
time are normal at early stages.
As mentioned above, multiple autoantibodies can be
detected in PSC [33] however, as Terjung et al. [36] sta-
ted, only p-ANCA might play some diagnostic role and
there is no correlation with clinical parameters or the
clinical spectrum of the disease.
3.3. Endoscopy
The most important diagnostic tool in the establish-
ment of PSC are the cholangiographic features of the
biliary tract. So far, endoscopic retrograde cholangiog-
raphy (ERC) remains the current gold standard for
imaging of the biliary tract in patients with PSC. The
intra- and/or extrahepatic bile ducts show localized or
multifocal strictures and intervening segments of normal
or dilated ducts. The cholangiographic appearance of
PSC includes a broad spectrum of features. While some
patients may have primarily extrahepatic bile duct alter-
ations, others might represent with normal common bile
duct but signiﬁcant intrahepatic changes. Li-Yeng and
Goldberg proposed a classiﬁcation of biliary tract alter-
ations in PSC. This classiﬁcation has been slightly mod-
iﬁed by Majoie et al. and amended by Rajaram et al.
(Table 2) [85,86]. The classiﬁcation separately grades
extra- and intrahepatic aﬀections of the bile ducts. Alter-
ations range from strictures with minimal dilatations to
basically complete loss of peripheral ducts. Examples of
radiographic PSC-associated alterations are shown in
Fig. 1. Endoscopically detectable alterations of the bile
ducts and biliary tree are limited to patients with large
bile duct PSC. Patients with small bile duct PSC present
with similar biochemical and histological features as
PSC, but with a normal cholangiogram [87]. Therefore,
a normal cholangiogram in a patient with cholestasis
cannot rule out PSC and requires additional diagnostic
tests, such as a liver biopsy. Vice versa, other cholestatic
liver diseases present with ERC features similar to PSC
Table 2
Cholangiographic classiﬁcation system for primary sclerosing cholangitis (modiﬁed from [112,146])
Intrahepatic
Type 0 No abnormalities
Type I Multiple strictures with normal caliber of the bile ducts or minimal dilatations
Type II Multiple short, bandlike strictures, saccular dilatations, decreased arborisation
Type III Despite adequate ﬁlling pressure only central branches ﬁlled; severe pruning, one or more outpouchings
Extrahepatic
Type 0 No abnormalities
Type I Irregularities of extrahepatic duct contour, without distant narrowing
Type II Segmental stenosis of extrahepatic duct, with smooth or irregular margin
Type III Irregular stenosis and beading of almost entire length of the common duct
Type IV Extremely irregular margin of the extrahepatic duct, diverticulumlike outpoutchings
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cholangitis may present with similar bile duct lesion in
the cholangiogram. Over recent years, various groups
reported an ischemic-like cholangiopathy with second-
ary sclerosing cholangitis and biliary cast formation in
patients who had survived prolonged intensive care
treatment (Fig. 2) [89–91]. Therefore, in addition to
ERC the patient’s history, laboratory tests and histology
have to be taken into account before the diagnosis of
PSC can be established. The risk of post ERCP pancre-
atitis is not increased in PSC patients if compared to
non-PSC patients [92,93]. While various studies found
the incidence of ERC-induced cholangitis to be approx-
imately 1% in unselected patient cohorts, van Milligen
et al. reported a 10% incidence of cholangitis in PSC
patients [94–97]. The increased risk of cholangitis sup-
ports the concept of antibiotic prophylaxis and addition
of antibiotics to the contrast agent. Stiehl et al. for
example, reported an ERC-related cholangitis in only
3.3% in their cohort of PSC patients, however, they con-
sequently administered peri-interventional i.v. antibiot-
ics and added antibiotics to the contrast agent [93].
Unfortunately, prospective and comparative data have
not been reported so far concerning this speciﬁc issue.
3.4. Magnetic resonance cholangiography (MRC)
Considering the inevitable risks of ERC for serious
complications such as cholangitis, pancreatitis, perfora-Fig. 1. Typical examples of PSC cholangiograms. (A) Type I intrahepatic a
alterations.tion or bleeding, alternative imaging procedures for
diagnosing PSC have become more desirable. Hence,
in recent years, magnetic resonance cholangiography
(MRC) as a non-invasive technique has increasingly
been used in the diagnosis of PSC.
A number of studies comparing both procedures
found that MRC showed a sensitivity of 80–91%, a spec-
iﬁcity of 85–99% and an accuracy between 83% and 93%
[98–103]. These results were only a little inferior to those
obtained with ERC-techniques with a sensitivity 89–
96%, speciﬁcity 8–100% and accuracy 85–97% [100,102].
Despite similar accuracy, the ﬁndings leading to the
diagnosis of PSC diﬀer for both modalities. ERC depicts
more bile duct stenoses and pruning while MRC ﬁnds
more skip dilatations together with bile duct occlusions
[103] (Fig. 3).
MRC has the advantage of visualizing bile ducts
proximal to a complete bile duct obstruction and of pro-
viding additional diagnostic information on the liver
parenchyma [100]. With the exception of some contrain-
dications such as claustrophobia or the existence of
metallic implants, diagnostic quality images can be
obtained by MRC in nearly all patients, particularly in
those individuals with biliary-enteric anastomosis or
gastric bypass as well.
However, because of inferior spatial resolution, severe
stenoses may appear as complete occlusions in MRC and
mild wall irregularities can be easily overestimated [103].
Furthermore, in cirrhotic patients and if PSC is limitedlterations, (B) Type II intraheptic alterations, (C) Type III intraheptic
Fig. 2. Secondary biliary sclerosis can mimick cholangiographic features of PSC. (A) The cholangiogram of a patient with ischemic-like cholangiopathy
and biliary cast formation after prolonged anamnestic polytrauma with sepsis and mechanical ventilation. (B) A biliary cast that had been removed from
the hepatic duct in this patient.
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cult to detect withMRC [99]. Naturally, one considerable
limitation of MRC is the fact that further diagnostic (i.e.Fig. 3. ERC with the corresponding MRC of two patients with PSC. Patient A
high-grade stenosis at the cystic duct junction. Patient B features a long-segmen
be profoundly narrowed in ERC while MRC accentuates the dilated bile ductsbrush cytology) or therapeutic (i.e. dilatation) interven-
tions are not possible, but very necessary in the majority
of cases according to one study [100].presents with multifocal strictures of the intrahepatic bile ducts and with a
t ﬁliform stenosis of the common bile duct; the intrahepatic ducts seem to
in intervening segments.
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in the diagnosis of PSC in asymptomatic patients with-
out cholestasis or with only moderate cholestasis. It
should be considered for follow-up studies or when a
complete visualization of the biliary tract is necessary.
However, ERC remains the gold standard at least for
initial diagnosis and PSC management including exclu-
sion of malignancy of stenotic bile ducts; in particular
when diagnostic or therapeutic interventions are
expected, then ERC is the procedure of choice
[100,101,103].
3.5. Histology
The main histopathological ﬁndings in PSC are less
speciﬁc and include portal ﬁbrosis (60–80%) and portal
lymphocyte inﬁltration (69%), even cirrhosis is present
in 9–33%. The more speciﬁc periductal ﬁbrosis with
the typical ‘‘onion skin”-pattern resulting in ductopenia
as well as bile duct proliferation is found in 8–55% and
cholestasis can be observed in 7–50% [47,104].
Ludwig et al. classiﬁed histological features in PSC in
four stages [47]: At stage I, changes such as cholangitis
or portal hepatitis are conﬁned to the portal tracts, at
stage II ﬁbrosis or hepatitis are also periportally found,
septal ﬁbrosis and/or bridging necrosis indicate stage
III, while biliary cirrhosis deﬁnes stage IV.
However, because of the merely non-speciﬁc changes
percutaneous liver biopsy is rarely diagnostic in PSC
and is used primarily to exclude other coexisting diseases
or to support the diagnosis in doubtful cases. A retro-
spective study revealed that liver biopsy in patients with
a known PSC (assured by ERC) added new information
and aﬀected clinical management in only 1.3% [105].
Moreover, serial liver biopsies demonstrated a high
degree of sampling variability [104], since PSC is a focal
disease, so the usefulness of liver biopsy for staging, as
some authors proposed, has to be questioned. There-
fore, histology is no longer included in current survival
models for PSC [17,106].
3.6. Diﬀerential diagnosis and variant syndromes
Other cholestatic liver diseases that feature similar
cholangiographic ﬁndings as PSC have already been
mentioned. In case of an AMA-negative cholestatic
disease with a normal cholangiogram, liver biopsy is
recommended as the next diagnostic step, to rule out,
among others, an AMA-negative PBC, an autoimmune
cholangitis and sarcoidosis or cholestatic hepatitis
[107]. If the histology is compatible with PSC and
IBD is present, small-duct PSC (sdPSC) can be
assumed.
Ludwig et al. [47] coined the phrase small-duct PSC
instead of the obsolete term ‘‘pericholangitis” as desig-
nation for a chronic hepatitis associated with IBD, anormal cholangiogram and with biochemical and histo-
logical features compatible with PSC. The question of
whether IBD presence is mandatory for the diagnosis
has not yet been deﬁnitively resolved. According to cur-
rent studies, only 3–17% of patients with sdPSC die or
undergo liver transplantation compared with 42–47%
in the group of patients with large-duct involvement.
In addition, up to the present time cholangiocarcinoma
(CC) has not been reported in patients with sdPSC [108–
111]. Approximately 12–16% of patients develop fea-
tures of large-duct PSC during follow-up. UDCA ther-
apy appears to improve liver biochemistry, however
does not delay disease progression [111].
An overlap syndrome of PSC and autoimmune hepa-
titis (AIH) is presumed in patients with PSC, who also
fulﬁl the diagnostic criteria for AIH. Based on the
revised AIH scoring system [112], overlap was found
in 1.4–8% of PSC patients [17,113,114]. Paediatric
AIH patients showed an overlap with primary sclerosing
cholangitis in 49% [115]. Patients with overlap syndrome
exhibited higher serum levels of aminotransferases, IgG,
total globulins and higher titers of autoantibodies. These
patients were younger at presentation, association with
IBD was less common [116] and their median histologi-
cal score was higher than in patients with PSC alone
[114]. Immunosuppressive therapy appears to be beneﬁ-
cial with a signiﬁcant reduction of aminotransferases
and the transplant-free survival appears to be higher
than in PSC alone [113,116].
Patients with IgG4-related autoimmune pancreatitis
(sclerosing pancreatitis) often feature sclerosing cholan-
gitis as an extrapancreatic manifestation. This type of
sclerosing cholangitis resembles PSC in the cholangio-
gram but responds well to steroid therapy. It is charac-
terized histologically by a marked lymphoplasmacytic
inﬁltration with IgG4-positive plasma cells and
CD4+/CD25+ regulatory T-cells [117–119]. On the
other hand, a recent study from the Mayo clinic found
elevated IgG4-levels in 9% of PSC patients [120]. These
patients had in addition signiﬁcantly higher levels of
total bilirubin and of alkaline phosphatase, a lower fre-
quency of IBD and a shorter time to liver transplanta-
tion. There were no diﬀerences in age, gender or in
history of pancreatitis. The authors speculated that this
special subset of PSC patients may behave similar to
patients with autoimmune pancreatitis and that treat-
ment of these patients with corticosteroids should be
considered.4. Surveillance
One of the major challenges for clinicians, with
regard to the limited long-term prognosis of PSC, is
an eﬀective surveillance strategy in the medical care of
these patients in order to select the optimum time for
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nancies as early as possible. Thus a number of studies
attempted to ﬁgure out clinical, biochemical, endoscopic
or imaging parameters which may help physicians to
identify the patients with reduced long-term prognosis
due to hepatic decompensation or cholangiocarcinoma
(CC). However, all the surveillance strategies described
are neither prospective nor are they based on patients
of diﬀering ethnicity enrolled by multiple centres from
various parts of the world.
4.1. Biochemical and clinical parameters for surveillance
Due to the fact that the prognostic scores for cir-
rhotic diseases such as the model for end-stage liver dis-
ease (MELD) or the Child–Pugh score do not assess
survival in PSC well, to date a couple of prognostic
scores which estimate survival of PSC patients have
been developed, e.g. the well known Mayo survival
model [106]. Age and bilirubin were identiﬁed as inde-
pendent predictive parameters in all of these scores
[16,17,106,121], whereas the histological stage was only
included in older scores. Low albumin proved to be of
prognostic relevance in the two current scores [17,106],
while aspartate aminotransferase could be identiﬁed as
an independent prognostic parameter only from the
Mayo group. Other clinical parameters which evolved
as independent prognostic factors in one or two of the
scores were splenomegaly, hepatomegaly or variceal
bleeding. Another recently published study identiﬁed
an aspartate to alanine aminotransferase ratio P1 as
predictor of liver-related death with an almost 4-fold
higher risk [122].
Multiple studies looked for risk factors or predictive
parameters for CC; however the fact that most of the
results of these studies were not reproducible, and in
some cases even contradictory, demonstrates the enor-
mous diﬃculty of predicting hepatobiliary malignancy
in PSC. Parameters found to be predictive only in single
studies which could not be veriﬁed in other studies were:
history of variceal bleeding and history of proctocolec-
tomy (mostly due to refractory UC) [123], smoking
[82,124], alcohol consumption [125], higher bilirubin
levels on admission, previous colorectal cancer, and no
UDCA treatment [126]. Three studies identiﬁed a longer
duration of IBD as a risk factor [124,126,127] and
several studies identiﬁed a recent diagnosis of PSC as
a predictor of malignancy [124,126–128]. At the time
of cancer diagnosis, patients with hepatobiliary carci-
noma present more often with abdominal pain accord-
ing to three studies [82,124,127]. Hence a patient with
a recently diagnosed PSC with severe symptoms and a
long history of IBD should be examined very carefully
in order to rule out the possibility of CC.
The detection of serum tumour markers such as car-
cinoembryonic antigen (CEA) or carbohydrate antigen19-9 (CA19-9) was regarded initially as a helpful diag-
nostic tool in diagnosing CC in PSC. Preliminary retro-
spective studies found suﬃcient accuracy for a
combined score of CA19-9 and CEA [129] respectively
signiﬁcantly higher levels of CA19-9 in PSC patients
with CC [82]. Also, three current retrospective studies
which used higher cut-oﬀ values between 100 U/ml
and 200 U/ml [124,125,130] found signiﬁcant correla-
tions with CC. However, the results of two prospective
studies in which serial tests of tumour markers were
performed were disappointing in predicting CC
[125,131]. The main disadvantage of tumour markers
is their unspeciﬁc increase in case of acute cholangitis
or dominant stenoses [132]. Furthermore, only
advanced cases seem to be detectable by CA19-9 which
makes it inappropriate for surveillance [130]. Serum
trypsinogen-2 was recently found to be superior to
CA19-9 in diﬀerentiating patients with PSC and CC
from patients with PSC alone [133]; further studies
are needed to support these promising results.
4.2. Imaging techniques for surveillance
Imaging techniques too are of restricted value in
the early detection of CC in PSC due to the fact that
they are unable to detect CC at a stage which allows
for curative resection or liver transplantation. Indeed,
in a retrospective study on 30 PSC patients with bil-
iary tract carcinoma, CT and MRI were able to
detect CC in about 85% [134], however this non-
blinded retrospective study had several limitations
and did not provide information on the patients’ out-
come. In another study on 48 patients with PSC and
CC, the diagnosis of CC was suspected in only 63%
by CT and in 46% by ultrasound (US) [127] and
the majority of cases were too far advanced for cura-
tive treatment.
Dynamic positron emission tomography with 18F-ﬂu-
orodeoxyglucose (FDG-PET) was found to be useful for
screening of CC in PSC patients, since in a study on 24
patients it detected (in contrast to CT) correctly 3 of 4
CC/high-grade-dysplasia and was false positive in only
1 of 20 patients [135]. However, other studies did not
conﬁrm these results [70], so that the value of FDG-
PET as a surveillance method in PSC should be evalu-
ated in prospective studies.
The sensitivity of ultrasound in detecting CC in PSC
is low; nonetheless, it might be useful to assess cirrhotic
complications of advanced disease. Furthermore, US
allows to detect gallbladder polyps, which are in about
50% of cases malignant in PSC [136] which would indi-
cate a cholecystectomy. Furthermore, due to the fact
that the risk of pancreatic carcinoma appears to be
increased more than 10-fold in PSC [15], ultrasound
might be useful for screening in this high-risk
population.
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Unfortunately, ERC alone has a low sensitivity and
speciﬁcity to discriminate between benign and malignant
bile duct stenoses [82,137]. Therefore, routine surveil-
lance ERCs have not been shown to be of signiﬁcant
beneﬁt for the patients. Increase in cholestasis however,
should trigger endoscopic examinations [124]. In addi-
tion to radiographic delineation of the biliary tree,
ERC can be complemented by brush cytology, forceps
biopsy, intraductal ultrasound and direct visualization
of the biliary tree using ‘through the scope‘ cholangios-
copy (Fig. 4). Depending on the various studies, the
published sensitivity of ERC guided biliary brush cytol-
ogy can be very low [138–140]. However, brush cytology
has a high speciﬁcity for CC [138–140]. The low sensitiv-
ity requires repeat examinations, if cytology is negative
while the cholangiogram is suspect of CC. ERC can be
performed to advance forceps in the bile duct and
obtaining histological samples. Advancing of rigid
biopsy forceps in the common bile duct can induce per-
forations in particular in the hand of the unskilled phy-
sician. Unfortunately, to date no wire guided biopsy
forceps has been introduced, so that performing a
biopsy in the hepatic ducts remains diﬃcult. However,
the combination of forceps biopsy and brush cytology
increases sensitivity [141]. Cholangioscopy enables
direct visualization of the biliary epithelium. In a recent
study from our department, Tischendorﬀ et al. demon-Fig. 4. Cholangiogram of a PSC patient. The arrow indicates a polypoid
mass in the hilar region. Forceps biopsy revealed CC.strated that cholangioscopy is superior to ERC alone
in discriminating between malignant and benign stric-
tures (Fig. 5) [142]. With the development of a 4-way
deﬂecting cholangioscope and cholangioscopy guided
biopsies further improvement in the diagnosis of early
CC may be achieved [143].
Intraductal ultrasound may be another important
technical addition for diﬀerential diagnosis of dominant
strictures. In addition to cholangioscopy, Tischendorﬀ
et al. studied the role of intraductal ultrasound to dis-
criminate between benign and malignant strictures. In
comparison to solely ERC, intraductal ultrasound
(IDUS) signiﬁcantly increased sensitivity from 62.5%
to 87.5% and speciﬁcity from 53.1% to 90.6% [144]. In
addition to the above mentioned methods, ERC can
be used to aspirate bile ﬂuid. Kubicka and colleagues
measured mutations in the K-ras oncogene in epithelia
derived from bile ﬂuid of PSC patients [145]. While k-
ras mutations can be detected in the bile of PSC patients
without CC, however, patients that were positive for k-
ras mutations were at a signiﬁcantly higher risk to
develop CC. Biliary insulin-like growth factor I (IGF-
I) is signiﬁcantly increased in patients with CC and
can distinguish between carcinoma and benign strictures
[146]. Whether these promising data can be applied for
PSC patients, still needs to be investigated.
Approximately 60–80% of patients with PSC suﬀer
from IBD [17,147]. UC constitutes the biggest group
with nearly 80% [17,147]. Chronic intestinal inﬂamma-
tion increases the risk of colonic neoplasms. A subse-
quent increase in colorectal cancer incidence has been
reported in association with ulcerative colitis. A cancer
incidence of approximately 9% and 30% after 20 and
30 years of disease has been reported [148]. Several stud-
ies have indicated that patients with UC and coexisting
PSC may be at an even higher risk for the development
of CRC [149–154]. Broome et al. reported an almost 5-
fold increase in the absolute cumulative risks of develop-
ing colorectal cancer or dysplasia for UC patients with
PSC after 20 years of colitis [154]. If possible, surveil-
lance colonoscopy should be performed during remis-
sion in order to allow diﬀerentiation between reactive
changes from dysplasia. Chromoendoscopy and zoom
colonoscopy might be helpful to unmask intraepithelial
neoplasia and guide biopsy [155,156].5. Treatment
5.1. Medical therapy
Present day data and clinical experience do not sug-
gest that PSC represents a disease which is curable by
medical therapy [157]. A cure would include the
improvement or normalization of abnormal cholestatic
biochemical features but more importantly the improve-
Fig. 5. Cholangiogram (A) and cholangioscopic appearance (B) of a benign stricture in a patient with PSC.
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biliary tree, which ultimately lead to biliary cirrhosis, to
episodes of cholangitis, and which carry the risk of cho-
langiocellular carcinoma. The only available drug that
combines a favourable toxicity proﬁle and can lead to
a reduction of cholestatic serum parameters is currently
ursodeoxycholic acid (UDCA). Predictive scores which
have been developed to assess the progress of PSC in
view of the clinical experiences of high interindividual
variability and unpredictable acceleration episodes
almost always contain serum bilirubin as a parameter
[16,77,106,121,158,159]. Between 1998 and 2000 four
such scores have been reported that employ bilirubin
in addition to age, histology, variceal bleeding, hepato-
megaly, inﬂammatory bowel disease, albumin, AST,
and haemoglobin [16,77,106,121]. From this perspective,
an improvement of the parameter bilirubin, common to
these four scores, would be a plausible indicator of an
improved prognosis. However, a number of controver-
sies surround the use of UDCA. In two studies by
Mitchell et al. and Harnois et al. published in 2001, an
improvement was documented using 20 mg/kg body
weight, and 25–30 mg/kg body weight, respectively
[160,161]. Both use UDCA doses which are considerably
higher than those common in the therapy of primary bil-
iary cirrhosis (PBC) (15 mg/kg body weight). From
these data a higher dose appeared to be more beneﬁcial
in PSC. However, a study analyzing UDCA in bile as a
function of oral UDCA dose found that doses exceeding
25 mg/kg body weight are not likely to be useful since
the maximum transport of UDCA into the bile levelled
oﬀ at this dose with no further increase [162]. After these
and other initial reports, a meta-analysis was published
in 2002 [162] which concluded that UDCA therapy
improved biochemical parameters but that the overall
beneﬁcial eﬀect in patients with PSC, in particular sur-vival beneﬁt, was uncertain. In 2005 a large study was
reported that appeared to conﬁrm this view. Olsson
et al. studied 219 PSC patients in a placebo-controlled
trial [163]. Treatment was carried out with 17–23 mg/
kg body weight of UDCA and a trend towards a better
survival and less need for transplantation was seen
which did not reach statistical signiﬁcance. A diﬀerence
in the incidence of CC was not observed. However, sta-
tistical analyses reported in this study concluded that
346 patients would have been required to reach statisti-
cal signiﬁcance. Based on the body of the literature
available, a positive eﬀect of UDCA at present cannot
be excluded and clearly larger placebo-controlled studies
are required. This will only be possible in multi-centre
approaches.
An additional eﬀect of UDCA has been seen in two
reports which observed a decrease of the dysplasia in
colon polyps associated with UDCA doses as low as
10–15 mg/kg body weight [164,165]. Although this
requires conﬁrmation in larger studies, the association
of PSC with ulcerative colitis in 75% of aﬀected individ-
uals would make this an interesting ancillary eﬀect of
UDCA therapy.
The issue of immunosuppression in PSC is controver-
sial and the majority of centres and publications do not
recommend the routine administration of corticoste-
roids and other immunosuppressants [157,166]. In PSC
one of the most feared and unpredictable complicating
factors is bacterial cholangitis and cholangiosepsis.
Immunosuppression would be expected to aggravate
this complication. In rare instances such as overlapping
features of PSC and autoimmune hepatitis (AIH),
immunosuppression may be of beneﬁt but this requires
rigorous documentation of AIH which includes biop-
sies, autoimmune serology and suggestive biochemistry
[167,168].
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Inﬂammatory alterations in PSC can lead to almost
complete stenosis of the extrahepatic biliary tree and
can cause acute deterioration of liver function and
more rapid progression to biliary cirrhosis (Fig. 4).
Such lesions are termed as dominant biliary strictures.
Endoscopic treatment of strictures can improve chole-
stasis and pruritus [91,169–171]. Several modes of
endoscopic treatment have been developed and
applied successfully in PSC patients. Endoscopic treat-
ment is especially aimed at strictures located in the
common bile duct and main hepatic ducts. Current
endoscopic therapy consists of either bougienage or
balloon dilation of strictures with or without concom-
itant placement of endoprotheses [92,93,171–175].
Nasobiliary catheter drainage and lavage with or with-
out instillation of corticosteroids have been success-
fully applied as well [176,177]. These endoscopic
treatment modalities are all aimed at maintaining bil-
iary patency and at inducing sustained improvement
of clinical and biochemical variables. Baluyut et al.
showed that endoscopic treatment has a beneﬁcial
eﬀect on survival in PSC patients when applying the
Mayo clinic survival model [175]. Cholangioscopy, as
an additional diagnostic tool revealed biliary stones
in 56% of PSC patients [178]. 30% were missed on
cholangiography and detected only by cholangioscopy.
Clinical improvement after removal of stones was
achieved in 63% of patients. Unfortunately, no ran-
domised trials have been published which compare
the various endoscopic treatment options for their eﬃ-
cacy in maintaining biliary patency. The limited num-
ber of patients and the very heterogenous patient
population hinders the realization of randomised
endoscopic trials. Therefore, so far, no general recom-
mendation can be given concerning the best endo-
scopic approach to dominant strictures. When
dominant strictures are treated endoscopically, it is
most important not to overlook the presence of CC.
Therefore, repeated brush cytologies and/or forceps
biopsies of suspicious areas should be obtained.
5.3. Liver transplantation (OLT)
In PSCpatients, survival has been shown to be reduced
both in symptomatic and in asymptomatic patients
[106,157], which is in part attributable to the inherent risk
of CC aﬀecting 10–20%of these patients and renders deci-
sion making for liver transplantation a formidable chal-
lenge. In addition, PSC patients with advanced
destructive cholangiopathy frequently exhibit only mild
signs of liver failure based upon coagulation abnormali-
ties, hypoalbuminemia, or complications of portal hyper-
tension [17]. The course of deterioration leading to liver
failure is often observed after long periods of clinical sta-bility and frequently proceeds rapidly following septic bil-
iary complications. This is not well predicted by the
aforementioned PSC scores and this is also true for the
model of end-stage liver disease (MELD) which is used
for organ allocation in the USA and as of 2006 in the
Eurotransplant member countries.
Two major problems deﬁne the challenges involved in
the indication for liver transplantation in PSC. Firstly,
timing is diﬃcult [179]. PSC patients are young and pre-
emptive liver transplantation carries a higher short-term
risk of OLT itself than the most likely short-term natu-
ral course of the disease. On the other hand, patients
who urgently require OLT because of advanced biliary
destruction frequently do not meet priority criteria cal-
culated by the MELD system. Secondly, the 161-fold
increase of CC risk [15] is an eventuality which may
eliminate the option of liver transplantation altogether
if evidence of CC is detected by diagnostic imaging pro-
cedures. The diagnosis of early CC is diﬃcult and pres-
ently there is no single diagnostic procedure
characterized by high sensitivity and speciﬁcity available
[124]. Moreover, those patients at risk cannot be reliably
identiﬁed.
In terms of practical management, the ﬁrst point can
only be addressed by careful clinical monitoring of PSC
patients in transplant centres with an experienced hepa-
tology team, where the likelihood of early complication
diagnosis and management, as well as the individualized
timing of listing for OLT is higher [17]. The second
point has been addressed in two centres by establishing
speciﬁc protocols for the management of hilar CC and
OLT [180,181]. Rea et al. reported a rigorous algorithm
for non-resectable hilar CC patients who were carefully
selected and capable of surviving chemotherapy, radia-
tion therapy and surgery. A multimodal approach
including neoadjuvant chemo-/radiation therapy,
brachytherapy, chemotherapy, laparotomy and OLT
was employed resulting in a 5-year survival of 82%,
which did not diﬀer from results in PSC patients with-
out CC [180]. However, although attractive, these inter-
disciplinary strategies are best limited to studies and
experienced liver transplant and hepatology centres.
Overall, the results of liver transplantation in PSC
are good (Fig. 6), leading to 10-year survival rates of
approximately 70% [182]. In our centre, the median
survival of PSC patients with CC was 12.7 months
and all PSC patients irrespective of OLT had a mean
survival of 112 months [124]. Recurrence after OLT
is diﬃcult to diagnose but appears to occur in up to
25% of patients [183]. Liver transplantation continues
to represent the only curative option in PSC. Future
developments will have to address the missing sensitiv-
ity and speciﬁcity of early CC detection, as well as the
clinical prediction of the disease course and conse-
quently, speciﬁc OLT allocation criteria for this group
of patients.
Fig. 6. Kaplan–Meier analysis of cumulative survival after liver trans-
plantation from 01/2003 to 08/2007 at Hannover Medical School
comparing 55 patients with PSC (incl. ﬁve patients with CC) and 318
patients with other chronic liver diseases (hepatitis B and C, alcoholic
liver disease, hepatocellular carcinoma and others). The log-rank-test
shows a signiﬁcant better survival of patients with PSC (p < 0.01).
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Surgical resection or liver transplantation is the only
curative option for patients with PSC-associated CC.
However, the prognosis of patients with CC is poor,
even after surgical resection. A large population-based
study recently showed that survival after surgery for
extrahepatic CC has dramatically improved since 1973.
However, patients with intrahepatic CC have achieved
an improvement in survival largely conﬁned to more
recent years. This may be explained by innovative devel-
opments in imaging technology, improvements in
patient selection and advances in surgical techniques
[184]. In the therapy of hilar CC, the most favourable
results with 5-year survival rates of 61% are achieved
by no-touch-technique, en-bloc-resection and wide
tumour-free margins [185].
Compared to patients with non-malignant diseases,
patients with PSC-associated CC have a worse progno-
sis after liver transplantation. Due to the shortage of
donor organs, liver transplantation for patients with
CC has therefore been abandoned by most liver centres.
The above mentioned non-randomised pilot study with
neoadjuvant radiochemotherapy reported excellent 5-
year survival rates of 80%, at least in a subset of patients
with PSC-associated CC. In one study liver transplanta-
tion with neoadjuvant chemoradiation achieved an even
better survival with less recurrence than conventional
resection [180]. There are presently no randomised con-
trolled studies using this neoadjuvant strategy and,
therefore, the value of neoadjuvant radiochemotherapy
and liver transplantation for patients with PSC-associ-ated CC is still unclear. Obvious limitations of this strat-
egy are a substantial drop out rate during the
neoadjuvant therapy due to tumour progression and
treatment-related complications, such as vascular com-
plications after liver transplantation [186].
Palliative therapy of PSC-associated CC includes
endoscopic management of biliary stenosis (dilatation,
stenting), treatment of bacterial cholangitis and systemic
chemotherapy. A randomised study with photodynamic
therapy of CC resulted in prolongation of survival (493
days versus 98 days; p < 0.0001), improved biliary drain-
age and better quality of life for the patients compared
with endoscopic stenting alone [187]. Although a ran-
domised study investigating the combination of chemo-
therapy and PDT is still not available, there is evidence
of synergistic antitumoural activity of local PDT and
systemic chemotherapy in cell culture experiments and
early clinical studies [188].
There is only a limited number of studies regarding
the systemic treatment options for biliary cancers. To
date, the best response rates have been achieved with
combination chemotherapies containing platinum ana-
logues and gemcitabine. In the absence of larger clinical
phase III trials, a standard chemotherapy for biliary
cancers does not exist today [189].6. Conclusion
Primary sclerosing cholangitis represents in many
ways one of the most intriguing challenges of current
hepatology. Its aetiology is still mysterious though a
number of promising experimental approaches enlighten
the diﬀerent aspects of pathophysiology. PSC is not a
classical autoimmune disease but the increasing under-
standing of underlying immunological mechanisms
stimulates further investigations; the interaction
between biliary epithelial cells and cellular and humoral
immunity and the search for triggers of a deregulated
immunity is of particular interest in this context. At
present, there is no eﬀective pharmacotherapy available,
thus new insights into pathophysiological mechanisms
will hopefully lead to new therapeutic innovations.
Advances of endoscopic techniques promise additional
possibilities in diagnosis and treatment. Even though
the clinical course of the disease is rather variable, the
mean survival of PSC patients is markedly shortened.
Cholangiocarcinoma is a frequent outcome of PSC with
a very poor prognosis. Therefore clinical management is
exceptionally demanding. Advances in new imaging
techniques expand the diagnostic options and allow
new views on the disease. Considering the high risk of
malignancy eﬀective and evidence-based surveillance
strategies based on a combination of endoscopic, imag-
ing and biochemical techniques are urgently required.
These will be beneﬁcial for the timing of liver transplan-
S52 T.J. Weismu¨ller et al. / Journal of Hepatology 48 (2008) S38–S57tation, the only curative treatment at present, and the
current allocation systems should account for the special
features of this disease.
Finally, signiﬁcant progress in the management of
PSC will depend on breakthroughs in the pathophysio-
logical understanding of this mysterious disease. These
studies will need to look at the site of action which is
the biliary tree. Thus endoscopic management will go
hand in hand with studies on aetiology and pathogenesis
that rely on the investigation of biological materials
obtained endoscopically from the site of action, e.g.
the biliary tree with its pathological changes, in particu-
lar bile duct epithelium and the pathognomonic domi-
nant biliary strictures. Hopefully, the years ahead will
be interesting for the sake of our patients.References
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